The cancer genetics testing provider acquired its new business unit from GE Healthcare.
By buying Clarient, NeoGenomics hopes to move closer to its goal of becoming America's top cancer genetic testing lab.
NeoGenomics and GE Healthcare will also collaborate on a bioinformatics initiative for personalized oncology.
The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.
The licenses provide non-exclusive access to the IP for research applications.
General Electric has been awarded
Originally published Oct. 3.
NEW YORK (GenomeWeb) – GE Healthcare today announced a deal between its affiliate Clarient Diagnostic Services and GlaxoSmithKline to create a network of clinical laboratories to identify genetic mutations associated with different tumor types.
Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013
GE Healthcare this week launched the illustra Single Cell GenomiPhi DNA amplification kit from.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.